A €3B cash-rich biotech rebuilt as a dealmaking vehicle: upside hinges on one great acquisition, downside on one expensive mistake.
Overview
Galapagos is undergoing a rare, sweeping transformation: from a European biotech known for internal small-molecule discovery (including filgotinib/Jyseleca) into a capitalized acquisition vehicle focused on sourcing external, clinically de-risked assets. After clinical/regulatory setbacks and major value destruction since 2020, the company has exited Jyseleca commercialization (sold to Alfasigma) and is winding down its CAR‑T division, prioritizing capital preservation over continued high-burn oncology investment. Reported 2025 revenue (€1.1bn) is largely a non-cash accounting release of deferred income from the 2019 Gilead collaboration; true recurring revenue is minimal. The investment case now centers on a fortress balance sheet (~€3.0bn cash/investments, near-zero debt) and a newly installed dealmaking leadership led by CEO Henry Gosebruch. Shareholder returns depend primarily on whether management can deploy the treasury into a value-creating late-stage acquisition or partnership and rebuild a sustainable pipeline and commercial revenue base.